US Breast Cancer Lumpectomy Market, Treatment Cost & Opportunity Analysis 2024

Report
100 Pages
March 2018
Region: United States
Kuick Research
ID: 4482546

“US Breast Cancer Lumpectomy Market, Treatment Cost & Opportunity Analysis 2024” Report Highlights:

Lumpectomy Procedure & Cost Involved
Lumpectomy & Mastectomy Reimbursement Analysis
Lumpectomy Market Analysis by Technology
Presence of Venture Capitalist influencing the Market
Porter’s Five Force Analysis
Lumpectomy Market Opportunity Projections: More Than US$ 10 Billion

Breast cancer is one of the most common forms of cancer globally with 99% of the breast cancer patients being women. Recent data indicates that about 266,120 new cases of invasive and 63390 cases of noninvasive breast cancer will occur by the end of 2018 in the US alone, making it a primary health concern for women in US where one in 8 women is bound to be diagnosed with breast cancer during her lifetime.

Inspite of alarming rates of breast cancer incidence, a decrease in breast cancer mortality has been observed in the last few years. Technological advancement in the healthcare industry and improvements in traditional surgical techniques have contributed immensely in the successful treatment of early stage breast cancer, saving the lives of millions of breast cancer affected women globally.

Removal of cancer effected breast, known as mastectomy is still the most preferred and effective method in treating early stage breast cancer (Stage 0, I, II & III). However, recent trends show that a majority of breast cancer affected patients are opting for less extreme approach in breast cancer treatment. Women in US currently show a high preference for breast conserving surgery that has led surgeons and oncologists to develop a novel and innovative alternative to mastectomy, widely popular as lumpectomy.

Lumpectomy is the removal of cancer affected lump or tumor from the breast while causing minimal tissue loss. This procedure aims at conserving the original shape and size of the breast while also ensuring the complete eradication of cancer cells. Additionally, a patient undergoing lumpectomy has been observed to have better outcome in post-surgical procedures such as breast reconstruction with better cost affectivity compared to mastectomy.

Lumpectomy was previously believed to be less effective than mastectomy. However, recent clinical studies have proved that lumpectomy followed by five to seven weeks of radiation therapy has better efficacy than mastectomy; which has led to a strong foundation of the lumpectomy market in the US with multiple factors fuelling its growth.

Key factors driving the growth of US lumpectomy market are the growing incidence of breast cancer and the rise in better breast cancer imaging methods such as the introduction of 3D tomography which have been immensely helpful in accurate and early detection of breast cancer lumps in dense breasts which remained undetected by traditional breast imaging techniques.

Lumpectomy specific devices such as margin probe by dune medical devices for identification of the tumor and normal tissue margin, ‘Savi scout’ for breast localization and surgical guidance (which is bound to replace traditional wire localization technique) and ‘Intrabeam’ by Carl Zeiss Meditech for targeted radiation delivery are few of the important tools that are bound to improve the outcome of lumpectomy surgery significantly. Further, innovative and promising implants like biozorb LP are also being developed for better outcome for post lumpectomy procedure like breast reconstruction.

Apart from the increased detection of early stage breast cancer, initiatives by government, better reimbursement and insurance and rise in venture capitalist are also some key factors fuelling the lumpectomy market growth. Owing to its superiority over mastectomy, lumpectomy might emerge as the dominant form of breast cancer surgery in the future with market opportunity of more than US$ 10 Billion by 2024.

The US lumpectomy market provides a detailed insight into the current market size, trends, opportunities and market dynamics. The report is an outcome of extensive research done on multiple factors governing the US lumpectomy market ranging from cost analysis of lumpectomy procedure, technology & tools involved to key industrial developments that are bound to impact the lumpectomy market. Finally, KuicK Research analysis of forecast and projections regarding the future of lumpectomy market indicate an exciting opportunity waiting in this highly profitable segment of breast cancer surgery.

1. Prologue to Breast Cancer & Lumpectomy

1.1 Lumpectomy - A Breast Conserving Strategy
1.2 A Safer & Efficient Alternative to Mastectomy

2. Lumpectomy - Opportunities in the US Breast Cancer Therapy Market

2.1 US Breast Cancer Market Size
2.2 Increasing Breast Cancer Incidence in the US
2.3 Combination of Lumpectomy & Radiation– Equivalent Efficacy to Mastectomy
2.3.1 Mastectomy v/s Lumpectomy Preference in American Women
2.3.2 Overall Survival & Recurrence Rates

3. Lumpectomy - Procedure & Cost Involved

3.1 Breast Cancer Mammogram & Biopsy Cost
3.2 Cost Involved During the Procedure
3.2.1 Lumpectomy plus Whole-Breast Radiation Therapy
3.2.2 Lumpectomy plus Partial-Breast Radiation Therapy (Brachytherapy)
3.3 Lumpectomy & Mastectomy Reimbursement Analysis
3.4 Post Lumpectomy Costs
3.4.1 Mastectomy or Mastectomy Plus Reconstruction
3.4.2 Additional Cost (Consumable, Lab, Imaging & Other Service Cost)
3.5 Cost Effectiveness of Lumpectomy

4. Current Market Scenario & Trends in Lumpectomy Breast Cancer Treatment

4.1 Increasing Breast Cancer Screening among American Women
4.1.1 Entry of Advanced Breast Imaging Techniques
4.1.2 Rising Awareness Regarding Breast Cancer Screening
4.1.3 Breast Cancer Incidence & Lumpectomy Preference in Men
4.2 Increasing Clinical Studies Proving Better Efficacy of Lumpectomy

5. Lumpectomy Market Analysis by Technology

5.1 MarginProbe - An Intra Operative Technology to Improve Lumpectomy
5.2 Savi Scout-Breast Localization and Surgical Guidance System
5.3 Biozorb LP for Better Cosmetic Outcome after Lumpectomy

6. Key Developments Affecting the US Lumpectomy Market

6.1 Focus of Key Industries in Early Stage Breast Cancer Segment
6.2 Introduction of Better Breast Cancer Screening Technology & Its Impact on the Lumpectomy Market
6.3 Expansion of US Lumpectomy Technology & Products to Global Platforms
6.3.1 iCAD Early Breast Cancer Screening Technology
6.3.2 Intrabeam System by Carl Zeiss Meditech

7. New & Better Breast Imaging Technology Driving Lumpectomy Market

7.1 Digital Breast Tomosynthesis (DBT)
7.2 Breast Cancer Genetic Screening Tests on the Rise
7.3 FDA Approval of Innovative Lumpectomy Technology
7.4 Magnetic MaMaLoc Technology – Localized Lumpectomy Procedure

8. Presence of Venture Capitalist influencing the US Breast Cancer Lumpectomy Segment

9. Porter’s Five Force Analysis of the Breast Lumpectomy Market

9.1 Threat of New Entrant
9.2 Bargaining Power of Patient
9.3 Bargaining Power of Service Providers
9.4 Intensity of Competitive Rivalry
9.5 Threat of Substitutes Procedures

10. Lumpectomy Market Analysis by End User

10.1 Hospitals
10.2 Oncology Research & Screening Centers

11. US Lumpectomy Market Dynamics

11.1 Market Driving Parameters
11.2 Market Growth & Acceptability Challenges

12. Future Forecast & Projections of the Lumpectomy Market

13. Competitive Analysis

13.1 Carl Zeiss Meditech
13.2 Cianna Medical
13.3 Clear Cut Medical
13.4 Dune Medical Devices
13.5 Endomagnetics
13.6 Focal Therapeutics
13.7 Hologic
13.8 iCAD
13.9 Medtronic
13.10 Sanarus

List of Figures:

Figure 1-1: Overview of Lumpectomy
Figure 1-2: Treatment Algorithm in Early Breast Cancer Patients
Figure 1-3: Global-Five Year Survival Rate in Breast Cancer by Stage
Figure 1-4: Lumpectomy v/s Mastectomy Overview
Figure 2-1: US v/s Rest of the World - Breast Cancer Market Size (%), 2018
Figure 2-2: US - Breast Cancer Prevalence & Incidence (Patients/Year), 2016-2018
Figure 2-3: US - Probability of Developing Breast Cancer in Women by Age(%), 2018
Figure 2-4: US - Probability of Breast Cancer by Ethnicity (%), 2018
Figure 2-5: Lumpectomy & Mastectomy - Estimated Market Size (%), 2018
Figure 2-6: US - Mastectomy v/s Lumpectomy Preference (%) , 2018
Figure 2-7: US - Five Year Survival Rate in Women (%), 2018
Figure 2-8: US - Five Year Survival Rate in Men (%), 2018
Figure 2-9: Efficacy of Lumpectomy v/s Mastectomy (%)
Figure 3-1: US - Lumpectomy Treatment Cost by Stage of Breast Cancer (US$/Patient), 2018
Figure 3-2: US - Lumpectomy Breast Surgery Cost (US$), 2018
Figure 3-3: Lumpectomy - General Overview of the Procedure
Figure 3-4: US - Mammogram Cost Analysis (US$/Test), 2018
Figure 3-5: US- Biopsy & Mammography Cost (US$/Patient), 2018
Figure 3-6: Recent Alternatives to Breast Cancer Biopsy
Figure 3-7: US - ONCOblot & Thermography Cost Analysis (US$), 2018
Figure 3-8: US - Whole Breast & Partial Breast Radiation Therapy Cost Analysis (US$), 2018
Figure 3-9: US - Average Lumpectomy plus Whole Breast Radiation Cost (US$), 2018
Figure 3-10: Intrabeam - Single Dose Radiation Therapy Cost Analysis (US$), 2018
Figure 3-11: US - Lumpectomy plus Breast Radiation Cost (US$), 2018
Figure 3-12: US - Mastectomy & Lumpectomy Reimbursement Analysis (US$), 2018
Figure 3-13: US - Breast Reconstruction Surgery Cost (US$), 2018
Figure 3-14: US - Breast Reconstruction Cost Post Lumpectomy (US$), 2018
Figure 3-15: US - Average Consumable, Lab & Additional Service Cost in Lumpectomy (US$/Patient), 2018
Figure 3-16: Comparative Cost Analysis of Mastectomy & Lumpectomy (US$), 2018
Figure 4-1: US - USPTF Estimated Screening Cost (US$ Billion)
Figure 4-2: US - Digital Mammography System Equipment Cost (US$), 2018
Figure 4-3: US - Epidemiology (Estimate) of Breast Cancer by Gender, 2018
Figure 5-1: Marginprobe - A Recent Advancement in the Lumpectomy Segment
Figure 5-2: MargineProbe - Clinical Efficacy Data proving it Efficacy (%), 2018
Figure 5-3: MarginProbe - Breast Re-Excision Reduction Rate (%), 2018
Figure 5-4: Savi Scout - Feature Overview
Figure 6-1: Sentimag - Key Features in Lumpectomy
Figure 6-2: Intrabeam - An Insight into its Key Features
Figure 6-3: US v/s Rest of the World-Intrabeam Centers (Number), 2018
Figure 7-1: Advantages of Novel Breast Tomography Technique over 2D Technology
Figure 7-2: Magnetic MaMaLoc Technology - Overview
Figure 8-1: US - Emerging Markets Affecting the Lumpectomy Segment
Figure 9-1: US - Lumpectomy Marker - Porter's Five Force Analysis
Figure 10-1: US - Recommended Frequency of Breast Cancer Screening by Age
Figure 10-2: US - Lumpectomy Market Size by End User (%), 2018
Figure 10-3: US - Out Patient Department Visits for Breast Cancer (Patients/State), 2017
Figure 10-4: US - Lumpectomy & Mastectomy Payment Source Analysis by Patients (Number), 2017
Figure 10-5: US - Cancer Research Funds across Major Research Centers (US$ Million), 2017
Figure 11-1: Driving Factors of the Lumpectomy Market
Figure 11-2: US - Lumpectomy Market Challenges
Figure 12-1: US - Lumpectomy Market Opportunity (US$ Billion), 2018 - 2024

Samples

LOADING...

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

Carl Zeiss Meditech
Cianna Medical
Clear Cut Medical
Dune Medical Devices
Endomagnetics
Focal Therapeutics
Hologic
Medtronic
Sanarus
iCAD

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€2371EUR$2,400USD£1,974GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€4348EUR$4,400USD£3,619GBP

Table of Contents

Samples

Companies Mentioned (Partial List)

Related Topics

Related Reports

Lumpectomy Market in US 2024-2028

Breast Cancer, An Issue of Surgical Oncology Clinics of North America. The Clinics: Surgery Volume 23-3

Metastatic Breast Cancer Treatment Global Market Report 2024

Breast Cancer Drugs Market by Type, Distribution Channel - Global Forecast 2025-2030

HER2 - Negative Breast Cancer - Global Strategic Business Report